GLP-2 and intestinal adaptation: the biological case for short bowel syndrome treatment

Glucagon-like peptide-2 (GLP-2) analogs treat short bowel syndrome by activating the GLP-2 receptor in the intestinal mucosa, directly promoting mucosal growth, enhancing nutrient absorption, and reducing the volume of parenteral nutrition a patient requires. This mechanism — intestinal trophic signalling — distinguishes the GLP-2 class from supportive care and makes it the only pharmacological approach specifically targeting intestinal adaptation in short bowel syndrome (SBS).

Short bowel syndrome arises when surgical resection leaves insufficient functional intestinal length to sustain adequate nutrient and fluid absorption. Patients face long-term or permanent dependency on parenteral nutrition — a burdensome, expensive, and complication-prone intervention. The GLP-2 receptor pathway offers a pharmacological route to intestinal rehabilitation: by stimulating crypt cell proliferation and reducing apoptosis in the intestinal epithelium, GLP-2 agonists can measurably improve absorptive capacity over months of treatment.

According to WHO and rare disease registries, SBS affects a small but medically intensive patient population, with parenteral nutrition dependency representing one of the highest per-patient costs in gastroenterology. The clinical and commercial logic for improving on first-generation GLP-2 therapy is therefore compelling: any agent that reduces parenteral nutrition volume or frequency more effectively — or that requires less frequent dosing — captures meaningful clinical and economic value.

Teduglutide’s position and the patent white space it leaves open

Teduglutide — originally developed by NPS Pharmaceuticals and covered by patents including US10130677B2 for its use in SBS patients with colon in continuity — established the clinical proof of concept for GLP-2 agonism in this indication. Its core composition and method-of-use claims defined the first wave of IP in this space. However, teduglutide’s daily subcutaneous injection requirement, its relatively short plasma half-life derived from native GLP-2 structure, and the narrowness of its original patient population claims have created identifiable white spaces that a new generation of assignees is actively targeting.

Patent analysis of the post-teduglutide filing landscape — drawing on PatSnap’s database of over 548 relevant documents — reveals that competitors are not simply replicating teduglutide’s chemistry. Instead, they are pursuing three distinct innovation vectors: structural modifications to the GLP-2 peptide backbone for improved metabolic stability; fusion-protein architectures to dramatically extend circulating half-life; and novel receptor agonist scaffolds that may not be structurally constrained by teduglutide’s core claims.

“Competitors are not simply replicating teduglutide’s chemistry — they are pursuing structural modifications, fusion-protein architectures, and novel receptor agonist scaffolds to escape the foundational IP and improve on dosing frequency.”

The geographic spread of filings is also significant. While early SBS GLP-2 patents were concentrated in the US and Europe, the current landscape includes substantial Chinese assignee activity — from Sichuan University, Guangdong Zhongsheng Pharmaceutical, and Shenzhen Salubris Pharmaceuticals — reflecting the growing role of Chinese pharmaceutical R&D in rare disease biologics. According to WIPO data on international patent filings, the Asia-Pacific region has become a significant contributor to peptide therapeutic IP across all therapeutic areas.

The next-generation GLP-2 analog pipeline: who is filing and what they claim

The next-generation GLP-2 SBS pipeline is populated by more than twelve distinct assignees spanning North America, Europe, and Asia-Pacific, each staking out differentiated IP positions through novel peptide modifications and delivery architectures. The breadth of this landscape — visible across more than 548 patent documents — signals that the competitive threat to teduglutide is multi-directional rather than concentrated in a single successor molecule.

Zealand Pharma has the most extensive visible IP position in next-generation GLP-2 analogs for SBS, with filings including US20150297693A1 and US20210024596A1 covering novel GLP-2 peptide sequences with amino acid modifications designed to enhance metabolic stability and half-life. These filings claim full agonistic activity at the GLP-2 receptor while achieving structural differentiation from teduglutide. A corresponding European application (EP3416672A1) extends this coverage across major pharmaceutical markets.

Shenzhen Salubris Pharmaceuticals has filed multiple international applications — WO2022152285A1, WO2023131178A1, and WO2024131891A1 — covering GLP-2 analog compounds for SBS, including specific claims for patients with residual colon (CN115869386A). This multi-filing strategy suggests a systematic effort to establish broad IP coverage across compound composition, indication-specific use, and formulation.

OBI Pharma has secured European patent protection (EP3421047B1) for GLP-2 receptor agonists and has continued filing US applications as recently as 2024 (US20240285741A1), indicating an active programme rather than legacy IP. Jiangsu Hengrui Pharmaceuticals has pursued a two-filing strategy — WO2021022935A1 and WO2023030442A1 — suggesting iterative improvement of its GLP-2 derivative series. Protagonist Therapeutics has filed both a GLP-2 receptor agonist application (WO2022271891A1) and a GLP-2 peptide analog application (WO2024036049A1), reflecting a broad-to-specific prosecution strategy.

Half-life extension technologies reshaping GLP-2 dosing in SBS

The single most consequential innovation vector in the next-generation GLP-2 pipeline is half-life extension: moving from teduglutide’s daily subcutaneous injection to weekly or less frequent dosing. Patent filings reveal three distinct technological approaches to achieving this, each with different IP implications and manufacturing complexity profiles.

Approach 1: Amino acid sequence modification

Zealand Pharma’s filings (US20150297693A1, US20210024596A1, EP3416672A1) exemplify the peptide backbone modification approach. By substituting specific amino acids in the GLP-2 sequence, these analogs achieve resistance to DPP-4 and other proteases, extending plasma half-life without requiring fusion to a large carrier protein. Jiangsu Hengrui’s GLP-2 derivative series (WO2021022935A1, WO2023030442A1) follows a similar strategy, as does Sichuan University’s CN115197309A, which explicitly claims improved stability and extended half-life through specific peptide modifications.

Approach 2: IgG Fc fusion

Hanmi Pharm’s filings (US20200338153A1, US20220175896A1) describe GLP-2 analogs fused to IgG Fc regions, leveraging the well-established FcRn-mediated recycling mechanism to dramatically extend circulating half-life. AstraZeneca’s US20220259288A1 also claims GLP-2 fusion proteins with extended duration of action using half-life extending moieties, with the SBS indication explicitly within scope. This approach produces larger molecular entities than peptide modifications alone, with corresponding implications for manufacturing cost and immunogenicity assessment.

Approach 3: Albumin fusion and other carrier strategies

Novo Nordisk’s US20230227527A1 describes GLP-2 fusion proteins using albumin or Fc regions, with explicit claims for use in treating SBS. Albumin fusion exploits the same FcRn recycling pathway as Fc fusion but with a different molecular architecture. Amgen’s WO2020243430A1 covers long-acting peptide analogs including GLP-2 analogs with extended half-lives, while Chugai Pharmaceutical’s US20230053285A1 describes long-acting GLP-2 compositions with extended half-lives for SBS treatment.

Combination approaches and geographic diversity in the SBS patent landscape

Beyond single-agent GLP-2 analogs, the SBS patent landscape contains a distinct cluster of combination therapy filings that represent a further layer of competitive differentiation. NAIA Metabolics has filed US20220193186A1 describing a composition and method for treating SBS using GLP-2 agonists combined with growth hormone, claiming synergistic effects on intestinal adaptation, mucosal growth, and reduction of parenteral nutrition dependency. Zhejiang University’s CN115590952A covers a similar combination approach using GLP-2 analogs alongside growth factors.

These combination patents are strategically significant because they claim therapeutic synergy — a separate layer of IP from the GLP-2 analog composition itself. A competitor holding a next-generation GLP-2 analog composition patent would still need freedom-to-operate around these combination method claims if they wished to co-administer growth hormone or growth factors in clinical practice. IP professionals conducting freedom-to-operate analysis in this space should include combination method claims in their scope, as recommended by guidance from the European Patent Office on method-of-treatment claim interpretation.

Geographic diversification of the pipeline

The geographic spread of GLP-2 SBS patent filings has expanded substantially from the US-Europe axis that characterised the teduglutide era. Chinese assignees — including Sichuan University (US10493126B2-related work and CN115197309A), Guangdong Zhongsheng Pharmaceutical (CN112851795A), Shenzhen Salubris Pharmaceuticals (multiple WO and CN filings), and Zhejiang University (CN115590952A) — now represent a material share of global innovation in this space. This pattern aligns with the broader internationalisation of pharmaceutical R&D documented by OECD in its science and technology indicators, where Chinese institutions have increased their share of global biomedical patent filings substantially over the past decade.

Korean assignee Hanmi Pharm, along with Peptron (WO2022048688A1), adds further Asia-Pacific representation. The practical consequence for drug developers and IP teams is that freedom-to-operate analysis in the GLP-2 SBS space now requires systematic coverage of Chinese and Korean national patent databases — not merely US, EP, and PCT filings. PatSnap’s Discovery platform indexes over 2 billion data points across 120+ countries, providing the geographic coverage this landscape requires.

The institutional diversity of filers — ranging from global pharmaceutical companies (Novo Nordisk, AstraZeneca, Takeda, Amgen) to specialist rare disease biotechs (Zealand Pharma, OBI Pharma, Protagonist Therapeutics) to academic institutions (Sichuan University, Zhejiang University) — suggests that GLP-2 SBS is attracting innovation from multiple ecosystem layers simultaneously. This diversity is characteristic of a therapeutic area transitioning from pioneer-phase to competitive-phase, where the foundational mechanism is validated but optimal molecular design remains contested. Research published in Nature reviews of gastrointestinal peptide pharmacology supports the view that GLP-2 receptor biology still contains unexplored territory relevant to drug design.